看多
Get in before earnings

Posted previously on this 
Following up with a new post as it is nearing catalysts and technicals have suggested that it has broke out of a long consolidation period
I personally think this is due for a major run where the March earnings call should bring a lot of positivity to this stock. I'll be expecting encouraging first quarter sales of Olinvyk, their FDA approved drug that could potentially replace morphine and address opioid shortage. TRVN is also expected to report on their top-line data for another drug TRV027 this quarter.
genengnews.com/covid-19-candidates/trevena-trv027/
4 months price target: $7
Long term price target: TBD

Following up with a new post as it is nearing catalysts and technicals have suggested that it has broke out of a long consolidation period
I personally think this is due for a major run where the March earnings call should bring a lot of positivity to this stock. I'll be expecting encouraging first quarter sales of Olinvyk, their FDA approved drug that could potentially replace morphine and address opioid shortage. TRVN is also expected to report on their top-line data for another drug TRV027 this quarter.
genengnews.com/covid-19-candidates/trevena-trv027/
4 months price target: $7
Long term price target: TBD
註釋
Dropped a significant amount since my post but overall market is seeing red too. Will be holding this through their earnings交易進行
Been averaging down on this免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。